Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2018 May 29;143(2):736–745.e6. doi: 10.1016/j.jaci.2018.05.011

Figure 8.

Figure 8

Three subjects with positive anti-Galectin-3 antibody responses studied longitudinally by ELISA and plotted against IgG4-RD-Responder Index (RI) on the right Y-axis. Yellow symbols indicate dates of B cell depletion therapy with rituximab, after which, anti-galectin-3 antibody titers consistently declined. The black arrow in Subject 336 indicates the initiation of low-dose prednisone that successfully maintained remission in this subject with a subsequent rise in anti-galectin-3 response.